Skip to main content

Table 6 Comparison of baseline EPH-30 domain scores at other points of follow up (baseline versus 6, 12 and 18 month visits). Values are expressed as median (range) with respective p values

From: A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

 Baseline6 mp12 mp18 mp
Pain domain56.8 (0–95.5)19.3(0–90.9)<  0.00111.4 (0–72.7)<  0.0019.08(0–56.8)<  0.001
Control and powerlessness75 (0–100)16.7(0–100)<  0.00116.7(0–100)<  0.00114.3(0–79.2)<  0.001
Emotional well-being54.2 (0–100)18.7(0–95.8)0.0125.4(0–75)<  0.00120.8 (0–68.3)<  0.001
Social support50 (0–93.6)15.6 (0–39.5)0.0312.5(0–93.7)<  0.00112.5(0–100)0.006
Self-image58.3 (0–100)22.5(0–100)0.00433.3(0–100)<  0.00133.3(0–91.7)0.001
Work domain45 (0–85)12.5(0–80)0.910 (0–80)0.0040 (0–70)0.001